AI assistant
SYNTARA LIMITED — Call Transcript 2013
Apr 22, 2013
65830_rns_2013-04-22_da33188f-2533-46b1-8948-b3de2ffe316f.pdf
Call Transcript
Open in viewerOpens in your device viewer
Media Release
23 April 2013
==> picture [153 x 23] intentionally omitted <==
==> picture [153 x 24] intentionally omitted <==
PHARMAXIS INVESTOR CONFERENCE CALL
Pharmaxis Ltd (PXS) expects to complete its analysis and announce the results of its Phase III clinical trial of Bronchitol in patients with bronchiectasis prior to opening of the market tomorrow, 24 April 2013. That announcement will have the effect of lifting the current trading halt over the company’s shares.
The company will hold an investor teleconference at 9.30am tomorrow after release of the announcement to discuss the results.
-
Telephone access (toll free): Australia: 1800 059 809 or 1800 606 599
-
USA/Canada: 1855 881 1339
-
UK: 0800 051 8245
-
NZ: 0800 453 055
-
Telephone access (metered): +61 2 9008 9005
Online access details are available on the Pharmaxis website home page at www.pharmaxis.com.au
A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.
SOURCE: Pharmaxis Ltd, Sydney, Australia CONTACT: Pharmaxis Investor Relations T: +61 2 9454 7200, F: +61 2 9451 3622, E: [email protected] Website: www.pharmaxis.com.au
Page 1 of 1